This report provides comprehensive information on the therapeutic development for Optic Neuritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Optic Neuritis and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Key Topics Covered:
- Optic Neuritis Overview
- Therapeutics Development
- Pipeline Products for Optic Neuritis - Overview
- Pipeline Products for Optic Neuritis - Comparative Analysis
- Optic Neuritis - Therapeutics under Development by Companies
- Optic Neuritis - Therapeutics under Investigation by Universities/Institutes
- Optic Neuritis Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Optic Neuritis - Products under Development by Companies
- Optic Neuritis - Products under Investigation by Universities/Institutes
- Optic Neuritis - Companies Involved in Therapeutics Development
- Biogen, Inc.
- Bionure Farma, S.L.
- Commence Bio, Inc.
- Lipocure Ltd.
- Mallinckrodt Plc
- Meta-IQ ApS
- Neuralstem, Inc.
- Teijin Pharma Limited
For more information visit http://www.researchandmarkets.com/research/lllhdf/optic_neuritis